Small Pharma applies expert intellectual property design to guide academic discovery to commercial product.
Our current project is a rapid-acting antidepressant with potential to transform depression treatment. Existing antidepressants take 6-12 weeks to work, and are ineffective in 40% of sufferers. Our DMT drug candidates have the potential to accelerate recovery through psychedelic assisted therapy.
Our current project is a rapid-acting antidepressant with potential to transform depression treatment. Existing antidepressants take 6-12 weeks to work, and are ineffective in 40% of sufferers. Our DMT drug candidates have the potential to accelerate recovery through psychedelic assisted therapy.
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $1.2M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Angel CoFu... | acfinvesto... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.04.2017 | - | $1.2M | - |
Mentions in press and media 5
| Date | Title | Description |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will con... |
| 03.06.2021 | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |
| 01.06.2021 | SMALL PHARMA INC. Small Pharma Inc. : Expands Phase I/IIa Clinical Trial With Additional Study Site | LONDON, June 1, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announces the expansion of its Phase I/... |
| 07.04.2017 | Small Pharma Raises £970K in Funding | Small Pharma, a London, UK-based pharmaceutical startup, raised £970k in total funding. The funding includes: – £830k in a funding round led by Chris Torrance, co-founder of Horizon Discovery and PhoreMost (who has also joined the board), w... |
| - | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |